siRNA Nucleotide Modifications for GST-π Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current siRNA agents for modulating GST-π expression in cancer tissues face challenges such as insufficient activity, off-target effects, and lack of serum stability, limiting their efficacy in treating malignant tumors.
Innovation Solution
Development of nucleic acid molecules, specifically siRNA sequences with modified nucleotides and structures, such as 2′-deoxy and 2′-fluoro substitutions, that form stable duplex regions for targeted gene silencing of GST-π, using lipid or liposomal formulations for delivery to enhance potency and reduce off-target activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional siRNA agents are used for GST-π gene modulation, then gene silencing activity is achieved, but serum stability is insufficient and off-target effects occur
Solution Approach 1:
The patent modifies the chemical parameters of siRNA nucleotides by introducing 2'-deoxy and 2'-fluoro substitutions. These parameter changes in the nucleotide structure enhance serum stability while maintaining or improving gene silencing activity, directly resolving the contradiction between reliability and stability.
Solution Approach 2:
The patent creates composite siRNA structures combining modified nucleotides (2'-deoxy, 2'-fluoro) with standard nucleotides in specific patterns. This composite approach optimizes both serum stability and gene silencing activity by strategically placing modified nucleotides at positions that confer stability without compromising target recognition.
2Reliability
If conventional siRNA agents are used for GST-π gene modulation, then gene silencing activity is achieved, but off-target effects increase
Solution Approach 1:
The patent modifies nucleotide parameters at specific positions (particularly in the seed region and flanking areas) to enhance target specificity. The 2'-deoxy and 2'-fluoro modifications alter the conformation and binding properties of the siRNA, reducing off-target effects while preserving on-target gene silencing activity.
3Reliability
If siRNA molecules with modified nucleotides are developed, then serum stability and potency are improved, but manufacturing complexity increases
Solution Approach 1:
The patent systematically varies nucleotide modification parameters (position, type, and pattern of 2'-deoxy and 2'-fluoro substitutions) to identify optimal sequences. This structured parameter optimization approach balances improved in vivo potency with manageable synthesis complexity by focusing modifications on critical positions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The siRNA molecules demonstrate significant tumor inhibition, increased serum stability, and reduced off-target effects, achieving a 2.8-fold reduction in tumor weight and 2-fold reduction in tumor volume, with IC50 values as low as 5 pM, effectively modulating GST-π expression and inhibiting cancer cell growth.
Implementation Method 1
a sense strand and an antisense strand, wherein the strands form a duplex region
Implementation Method 2
the nucleic acid siRNA molecules for inhibiting expression of GST-π may include 2′-deoxy nucleotides, 2′-O-alkyl substituted nucleotides, 2′-deoxy-2′-fluoro substituted nucleotides
Data Source
AI summary
This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.